When can you start assessing how you feel with CBD?

Unlike a medicine whose expected effect is defined and measurable, wellbeing CBD has no therapeutic indication validated by the French authorities (MILDECA). What is being assessed is therefore essentially subjective: perceived quality of rest, level of relaxation, muscular comfort, integration into the evening ritual. This subjective nature calls for an observation period long enough to smooth out day-to-day variability, and for honesty about the limits of self-assessment (placebo effect, context effect, ritual effect).

Immediate sensations appear depending on the route of administration: sublingual, 15 to 45 minutes (Tmax 1-2h according to Millar et al., 2018); oral (capsule, infusion), 1 to 2 hours; vaporisation, a few minutes but shorter-lasting; topical, immediate local effect. These onset times say nothing about the usefulness of durably integrating the product into your routine, which is what the assessment window seeks to observe.

This benchmark, used in the communications of serious brands and in several practical wellbeing guides, is neither an ANSM standard nor a HAS recommendation. It reflects the time generally needed to stabilise a new routine, smooth out daily variations in how you feel, and allow a before/after comparison. An assessment made after two or three days of use does not support any conclusion.

First fix the variables: a single product, a single route (sublingual OR oral OR topical), a stable dose (for example 5-10 mg per serving, 1-2 times a day) and a stable schedule. Then keep a brief journal, a few lines a day: time and dose, sensations within the half-hour, perceived quality of rest the following day (score from 1 to 10), level of tension felt (1 to 10), any adverse effects. Finally, limit external variables: regular sleep, stable alcohol consumption, no major change of routine and no simultaneous introduction of another supplement.

Three readings are possible. You note a positive trend on the subjective indicators: you may choose to continue the routine. You note no appreciable change: that is a legitimate answer, CBD does not suit everyone. You note recurring adverse effects (marked fatigue, digestive problems): stop the product, adjust the dose or change route.

Expecting a medical effect, since no French authority has validated any therapeutic effect. Changing product every week, which makes assessment impossible. Over-interpreting one good night, given that natural variability is high. Combining with a medicine without medical advice, since CBD is metabolised by the CYP3A4 and CYP2C19 cytochromes common to many treatments. Hoping for a "stronger" effect by doubling the dose, which mainly increases the risk of adverse effects without any gain in how you feel.

The ANSES advises against CBD for pregnant and breastfeeding women and for minors. On 9 February 2026 the EFSA published a provisional safe daily dose of 0.0275 mg/kg/day (approx. 2 mg/day for 70 kg), an invitation to moderation. The French legal framework is set by the Conseil d'État ruling of 29 December 2022: THC ≤ 0.30% in the finished product. To structure a first purchase, see our guide to the essential beginner's questions.

Should CBD be taken every day during the assessment?

Yes, to stabilise the routine and smooth out variability. Irregular use makes assessment impossible.

Can several products be assessed in parallel?

No. Testing a single product at a time is the condition for being able to attribute what you feel to that specific product.

How do you know whether the effect felt is real or placebo?

You cannot know with certainty through self-assessment. The placebo effect is documented and is part of what you feel, without making it illegitimate: it simply invites you not to over-interpret your sensations.

What should I do if I feel nothing after six weeks?

Change route, change cannabinoid profile, or conclude that CBD does not suit you. All these answers are legitimate; CBD is not a medicine and is not right for everyone.